The company, which filed 21 abbreviated another drug applications (ANDAs) in the US marketplace in prior fiscal, campaign to launch 10-12 products in the current fiscal.
"We maintain close to not far off from 100 filings [for the US] with the aim of are still awaiting approvals," Lupin Managing Director Kamal Sharma thought, accumulation not far off from 10-12 products were likely to be unfurnished in place of launch inside the fiscal.
"Lupin will pick up again to kind not far off from 25-30 filings specifically in niche areas and has every time alert on control released, sustained liberation products which are challenging to develop, get pleasure from senior margins and maintain a smaller amount competition as single requires range as well as knowledge and IP prowess to develop them," Sharma added.
He thought ANDA approvals are in a jiffy taking not far off from 26-28 months from an usual 12 to 14 months earlier in place of launching generics in the US marketplace.
"Not withstanding the delays in approvals in the American marketplace, Lupin has built up a very differentiated and a highly qualitative generics pipeline in place of the US," Sharma thought.
Globally, the safe expects to launch virtually 50 products, together with around 30 products in India.
Besides, the company campaign to launch 10 products in the Japanese marketplace through its arm Kyowa Pharmaceutical in the current fiscal as it eyes to cash in on the topical Indo-Japan trade promise with the aim of opened the doors in place of the country's generic medicines near.
With the introduction of the 10 another products, Lupin expects revenues from the Japanese marketplace to grow by 20% in the subsequently fiscal.
The company, which operates in Japan through its subsidiary Kyowa Pharmaceuticals Industry, will dispatch a target marketplace size of close to $3 billion through these another launches.
The company's revenue expenditure on R&D amounted to Rs 483.4 crore, 8.5% to get sales as contrary to Rs 357 crore, 7.5% to get sales in FY10.
The company besides campaign to launch 5-6 products in Europe this fiscal.
The company has filed 33 marketing authorisation claim (MAA's) with European the system throughout FY11, its chief continually in a single fiscal time.
Its cumulative filings with the European regulatory the system in a jiffy attitude by the side of 91 with the company having traditional 44 approvals to engagement.
The European organization grew 30% throughout FY11.
Lupin's consolidated get sales crore in place of the time ended protest 31, 2011 stood by the side of Rs 5,706.82 crore.